Structured Summary
Abstract
A genetically engineered, fully humanized immunoglobulin G4 monoclonal antibody that binds to the PD-1 RECEPTOR, activating an immune response to tumor cells. It is used as monotherapy or in combination with IPILIMUMAB for the treatment of advanced malignant MELANOMA. It is also used in the treatment of advanced or recurring NON-SMALL CELL LUNG CANCER; RENAL CELL CARCINOMA; and HODGKIN'S LYMPHOMA.
MeSH Record
Classification
Broader headings
Related Concepts
Knowledge Graph
Drag nodes to rearrange; hover to trace links; click a node to open its page.
Drug Class
Pharmacological Action
MeSH Record
Synonyms
10 entry terms
- BMS-936558
- MDX-1106
- ONO-4538
- Opdivo
- BMS 936558
- BMS936558
- MDX 1106
- MDX1106
- ONO 4538
- ONO4538
MeSH Record
Aspects Covered
24 allowable subheadings
Indexed with the subheadings administration & dosage, adverse effects, analysis, biosynthesis, blood, cerebrospinal fluid, chemistry, classification, drug effects, economics, genetics, history, immunology, isolation & purification, metabolism, pharmacokinetics, pharmacology, physiology, poisoning, radiation effects, therapeutic use, toxicity, ultrastructure, urine.
MeSH Record
History Note
2019 (2010)
MeSH Hierarchy
Tree Numbers
AMA Style
References
- National Library of Medicine. Nivolumab. Medical Subject Headings (MeSH). 2026. Unique ID D000077594. http://id.nlm.nih.gov/mesh/2026/D000077594
- Nivolumab. In: Wikipedia. https://en.wikipedia.org/wiki/Nivolumab
- Nivolumab. In: Wikidata. https://www.wikidata.org/wiki/Q7041828